New combo attack on tough head and neck cancers
NCT ID NCT02586207
Summary
This study tested whether adding a new immunotherapy drug (pembrolizumab) to the standard treatment of chemotherapy plus radiation could be safe and more effective for people with locally advanced head and neck cancer. All 59 participants received the combined treatment. The main goal was to check for side effects, while also looking for early signs that the combination could help eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanford Health Cancer Center
Sioux Falls, South Dakota, 57104, United States
-
Sanford-Bismarck Medical Center
Bismarck, North Dakota, 58501, United States
-
Sanford-Roger Maris Cancer Center
Fargo, North Dakota, 58122, United States
-
UCSD Moores Cancer Center
La Jolla, California, 92093-0698, United States
Conditions
Explore the condition pages connected to this study.